On September 15, 2008, Galderma Labs quietly removed its Pliaglis Cream 7%/7% from the market. The product consisted of lidocaine and tetracaine, and was marketed for facial laser procedures.
A terse message published on the Pliaglis Web site stated, "We [Galderma] took this action because of recurring inconsistent viscosity (thickness) of the product formulation. Our testing has found significant levels of variability in the viscosity parameter, resulting in a thicker cream which can make application of the product difficult."
The company claims that the product is safe, but according to Plasmetic.com, anecdotal reports have circulated that the product was "a pain to apply and an equal pain to remove."
[Source: Galderma Laboratories/Plasmetic.com]